Availability And Accessibility To Optimal Medical Therapy For Heart Failure In Latin America And The Caribbean

Francisco Uribe,Juan Gomez-Mesa,Manuela Escalante,FRANCISCO URIBE,Mario Speranza,Eduardo Perna,Elaine Nuñez,Israel Marín Soria,Manuel N. Abi-Rezk,David Rodriguez,Felix Nunura
DOI: https://doi.org/10.1016/j.cardfail.2023.10.192
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction The management of heart failure (HF) includes pharmacological strategies to control symptoms and increase survival rates. Current management guidelines provide recommendations about these strategies; however, their availability and access may be limited in different regions of the world, including Latin America and the Caribbean (LA&C). Objective Evaluate the availability and accessibility to optimal medical therapy (OMT) for HF patients in LA&C, including beta blocker (BB), angiotensin converting enzyme inhibitor (ACEI) / angiotensin receptor antagonist (ARB) / angiotensin receptor-neprilysin inhibitor (ARNI), mineralocorticoid receptor antagonist (MRA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) Methodology The Council on Heart Failure and Pulmonary Hypertension (CIFACAH) of the Inter-American Society of Cardiology (SAIC) conducted a survey to evaluate the availability and access (cost paid by patient) of pharmacological, interventional and surgical options for HF in February 2023. Delegates from 21 LA&C countries that are part of the SIAC received and completed the survey. Results Regarding OMT, 100% of the countries have at least one BB, one ACEI, one ARB and one MRA available for HF treatment and ARNI and SGLT2i are available in 90% of countries (Table 1).The survey classified access to OMT as the percentage of the cost / value of medication that must be paid by the patient to access the specific therapy, as follows: 0%: No additional payment; <50%: pay for lest that 50% of the cost; 50-99%: Pay for most of the cost; 100%: Pay for all the cost.At least one BB of the OMT is available at 0% (No additional payment) in 76% of the countries, one ACEI / ARB / ARNI in 71%, one MRA in 71% and one SGLT2i in 42% of the countries (Table 2). By the other side, most of the available options for OMT are available in more than 86% of countries when patients can afford the hole cost (100%) of the medications. Conclusion In most LA&C countries, OMT is available with at least one medication from each pharmacological group. Most of the countries have health care systems that cover a percentage of the medication cost. Based on that, few countries have access to OMT at no cost, but in most of the countries there is a possibility to access to at least one medication of the OMT paying 100% of the value of the medications.
cardiac & cardiovascular systems
What problem does this paper attempt to address?